Evaluation of the Causes and Disease Processes of Chronic Lung Disease - Full Text View

Sponsored by:	National Heart, Lung, and Blood Institute (NHLBI)
Information provided by:	National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:	NCT00001183

Purpose

Chronic lung diseases are disorders associated with abnormalities in any of the structures involved in the process of breathing and bringing oxygen into the lungs and blood. This includes abnormalities in the airways, lungs, blood vessels in and around the lungs, and the tissue covering the lungs (pleura).

The purpose of this research study is to evaluate patients referred to the Pulmonary-Critical Care Medicine Branch (P-CCMB) of the National Heart, Lung, and Blood Institute (NHLBI) in order to;

Develop a better understanding of the causes and disease processes involved in disorders of the lungs
Identify patients eligible to participate in other P-CCMB research studies

Condition
Lung Disease

U.S. FDA Resources

Study Type:	Observational
Official Title:	Comprehensive Evaluation of the Etiology and Pathogenesis of Chronic Lung Disease (Screening Protocol)

Further study details as provided by National Institutes of Health Clinical Center (CC):

Study Start Date:

March 1982

Detailed Description:

The chronic lung diseases are those disorders associated with functional and/or structural derangement to the alveolar structures, airways, pulmonary blood vessels, pleura and/or mediastinum. The purpose of this project is to permit the comprehensive evaluation of patients referred to the Pulmonary-Critical Care Medicine Branch (P-CCMB) in order to: (1) develop an understanding of the etiology and pathogenesis of these disorders; and (2) identify individuals who will be suitable candidates for other P-CCMB protocols.

Eligibility

Ages Eligible for Study:	10 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

INCLUSION CRITERIA:

Symptoms consistent with pulmonary disease.

May have family history of lung disease.

Patients with diseases of organs with known association with lung disease.

EXCLUSION CRITERIA:

Persons with no clinical evidence of lung disease.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00001183

Contacts

Contact: Patient Recruitment and Public Liaison Office	(800) 411-1222	prpl@mail.cc.nih.gov
Contact: TTY	1-866-411-1010

Locations

United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike	Recruiting
Bethesda, Maryland, United States, 20892

Sponsors and Collaborators

National Heart, Lung, and Blood Institute (NHLBI)

More Information

NIH Clinical Center Detailed Web Page This link exits the ClinicalTrials.gov site

Publications:

Fulmer JD, Roberts WC, von Gal ER, Crystal RG. Morphologic-physiologic correlates of the severity of fibrosis and degree of cellularity in idiopathic pulmonary fibrosis. J Clin Invest. 1979 Apr;63(4):665-76.

Hunninghake GW, Gadek JE, Kawanami O, Ferrans VJ, Crystal RG. Inflammatory and immune processes in the human lung in health and disease: evaluation by bronchoalveolar lavage. Am J Pathol. 1979 Oct;97(1):149-206.

Crystal RG, Gadek JE, Ferrans VJ, Fulmer JD, Line BR, Hunninghake GW. Interstitial lung disease: current concepts of pathogenesis, staging and therapy. Am J Med. 1981 Mar;70(3):542-68. Review. No abstract available.

Study ID Numbers:	820032, 82-H-0032
Study First Received:	November 3, 1999
Last Updated:	October 24, 2008
ClinicalTrials.gov Identifier:	NCT00001183
Health Authority:	United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):

Computed Tomography
Fiberoptic Bronchoscopy
Pulmonary Function Testing

Cardiopulmonary Exercise Testing
Allergen Skin Testing
Chronic Lung Disease

Study placed in the following topic categories:

Respiratory Tract Diseases
Lung Diseases

ClinicalTrials.gov processed this record on January 15, 2009